Identify and assess the development and commercialization of generics and biosimilars Identification of Potential Generic and Biosimilar Entries Scenarios Related to Anticipated and Most Likely Timing of Market Entry Pipeline Analysis Generic / Biosimilar Launch Analogs
Why DS IP for Generic/Biosimilar Outlook Assessment ?
DS IP works with pharmaceutical businesses to help them make educated, strategic decisions about the commercialization and lifetime management of their products. When your drug confronts loss of exclusivity, whether through patent and exclusivity expiration or patent challenges, it is one of the most significant junctures in its lifespan.
It's critical to have a current understanding of the generics landscape if this happens. We're here to assist you. We begin by presenting customers with a list of probable generic / biosimilar entries, as well as their anticipated timeline and market launch strategy.
We also discover and assess generic and biosimilar development and commercialization, including an examination of any issues that may affect a generic's likelihood of approval or Complete Response Letter. We have a large analogue basis of new commercial models, including mapping generic ecosystems.
Work with DSIP Global
Reliable, methodical and delivered to a standard you can put in front of your client.
Start a Project →